These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9177864)

  • 1. A murine model of human myeloma bone disease.
    Garrett IR; Dallas S; Radl J; Mundy GR
    Bone; 1997 Jun; 20(6):515-20. PubMed ID: 9177864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
    Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
    Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
    Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between a murine myeloma cell line and bone marrow stromal cells.
    Bradley TR; Kriegler AB; Verschoor SM; Tzelepis SM; Cooper IA
    Exp Hematol; 1996 Feb; 24(2):307-9. PubMed ID: 8641357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.
    Manning LS; Berger JD; O'Donoghue HL; Sheridan GN; Claringbold PG; Turner JH
    Br J Cancer; 1992 Dec; 66(6):1088-93. PubMed ID: 1457349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
    Dallas SL; Garrett IR; Oyajobi BO; Dallas MR; Boyce BF; Bauss F; Radl J; Mundy GR
    Blood; 1999 Mar; 93(5):1697-706. PubMed ID: 10029599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
    Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
    Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.
    Pagnotti GM; Chan ME; Adler BJ; Shroyer KR; Rubin J; Bain SD; Rubin CT
    Bone; 2016 Sep; 90():69-79. PubMed ID: 27262776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce BF; Mundy GR; Roodman GD
    Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.
    Lwin ST; Fowler JA; Drake MT; Edwards JR; Lynch CC; Edwards CM
    Mol Cancer; 2017 Feb; 16(1):49. PubMed ID: 28241871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.
    Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
    Bone; 2003 Sep; 33(3):283-92. PubMed ID: 13678768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
    Sharma R; Williams PJ; Gupta A; McCluskey B; Bhaskaran S; Muñoz S; Oyajobi BO
    Oncotarget; 2015 Aug; 6(25):21589-602. PubMed ID: 26009993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
    Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
    Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.
    Tsunenari T; Koishihara Y; Nakamura A; Moriya M; Ohkawa H; Goto H; Shimazaki C; Nakagawa M; Ohsugi Y; Kishimoto T; Akamatsu K
    Blood; 1997 Sep; 90(6):2437-44. PubMed ID: 9310495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.